WCCT Global launches Orphan Drug program, In-Site patient recruitment
WCCT Global, a Southern California-based CRO, has announced a specialized program to conduct clinical research for sponsors engaged in Orphan Drug development.
Aside from the often referenced technical and commercial hurdles which must be overcome before launching a development program for an orphan indication, the necessity to attain adequate patient recruitment for safety and efficacy trials in support of the intended orphan indication offers an equal or greater challenge.
WCCT Global's proprietary In-Site patient recruitment method, which utilizes multiple levels of advanced digital technologies designed to work, in concert, to facilitate successful patient recruitment, focuses on identification of desired patients based on the utilization of multiple proprietary patient databases.
WCCT Global can not only locate patient groups, but determine the best sites to conduct clinical trial, making orphan disease recruitment more efficient for the investigative site and, ultimately, for the sponsor.
In-Site is an advanced digital advertising process by which WCCT Global can create an in-depth psychographic based on the orphan indication and apply specific targeting methods across digital and social media outlets to ensure ideally targeted patient access.
Jon Rojas, WCCT Global's chief operating officer, said, "Our In-Site proprietary recruitment tool can play a vital role leading to the successful recruitment of clinical trials in support of Orphan Drug development programs."